Related Experiment Videos
Natural antibodies to factor VIII
S Lacroix-Desmazes1, A Moreau, A Pashov
1INSERM U430 and University Pierre et Marie Curie, Hôpital Broussais, Paris, France. Panoix@hbroussais.fr
Seminars in Thrombosis and Hemostasis
|August 5, 2000
Summary
Natural and autoimmune anti-factor VIII antibodies share similarities but differ in origin. Some inhibitors arise from pre-existing B cells, while others develop through antigen-driven maturation, impacting treatment strategies for hemophilia A patients.
Area of Science:
- Immunology
- Hematology
- Autoimmunity
Background:
- Anti-factor VIII antibodies serve as a model for studying natural autoreactivity, disease-associated autoimmunity, and antigen-driven immune responses.
- Natural anti-factor VIII antibodies in healthy individuals, spontaneous inhibitors in autoimmune disease patients, and immune inhibitors in multitransfused hemophilia A patients offer insights into immune responses to factor VIII.
Purpose of the Study:
- To investigate the relationship between natural autoreactivity, disease-associated autoimmunity, and antigen-driven immune responses to factor VIII.
- To explore the characteristics and origins of anti-factor VIII antibodies in different clinical contexts.
Main Methods:
- Comparative analysis of isotypic distribution and epitope mapping of natural and disease-associated anti-factor VIII antibodies.
- Studies of cross-reacting idiotypes to differentiate populations of anti-factor VIII antibodies in patient plasma.
Main Results:
- Natural and disease-associated anti-factor VIII antibodies are not easily distinguished by isotypic distribution or epitope mapping.
- Factor VIII inhibitors in patient plasma comprise two populations: those from pre-existing B cells (similar to natural antibodies) and those from affinity-matured, hypermutated B cell clones.
Conclusions:
- Anti-factor VIII antibodies represent a valuable model for understanding immune responses to a single human protein.
- The presence of distinct antibody populations has implications for understanding and potentially treating patients with anti-factor VIII inhibitors, particularly in hemophilia A.